Cargando…
Novel Perspectives in Immune Checkpoint Inhibitors and the Management of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma
SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) is a huge worldwide healthcare burden. The incidence of non-viral causes of hepatocellular carcinoma, such as non-alcoholic steatohepatitis (NASH), is rising. The introduction of immune checkpoint inhibitors (ICI) has led to a paradigm shift in the syst...
Autores principales: | Chan, Landon L., Chan, Stephen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946632/ https://www.ncbi.nlm.nih.gov/pubmed/35326677 http://dx.doi.org/10.3390/cancers14061526 |
Ejemplares similares
-
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives
por: Federico, Piera, et al.
Publicado: (2020) -
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
por: Lee, Choong-kun, et al.
Publicado: (2022) -
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma
por: Rios, Rafael S., et al.
Publicado: (2021) -
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management
por: Cholankeril, George, et al.
Publicado: (2017) -
Natural Progression of Non-Alcoholic Steatohepatitis to Hepatocellular Carcinoma
por: Ramai, Daryl, et al.
Publicado: (2021)